Allgenesis Program Selected for RESI Taipei Innovation Challenge
Allgenesis sees Excellent Safety, Tolerability, and Signs of Efficacy from its Ongoing POC Phase 2a Study of AG-86893 in Patients with Pterygium
2019-10-18Allgenesis: Final Database Lock Reaffirms Excellent Safety, Tolerability, and Signs of Efficacy from POC Phase 2a Study of AG-86893 in Patients with Pterygium
2020-01-21Taipei, Taiwan/ November 14th, 2019
Allgenesis Biotherapeutics was selected as a finalist at the RESI Taipei Innovation Challenge held on November 14th, 2019. Allgenesis presented the company’s retinal program highlighting the potential of its novel bi-specific fusion protein, AG-73305.
“RESI Taipei was a great venue to showcase Allgenesis’ project portfolios to investors from Taiwan and overseas in attendance”, said Dr. Madhu Cherukury, CEO of Allgenesis.
“We believe our bi-specific fusion protein targeting integrins and VEGF pathways can provide additional therapeutic benefits compared to anti-VEGF monotherapies alone”, said Dr. Tan Nguyen. “We are thrilled to have met investors who were excited to see new innovations in the treatment of retinal diseases that have been dominated by two blockbuster medicines for some time, namely Eylea(R) and Lucentis(R)”, added Dr. Cherukury.
For fundraising, out-licensing or co-development discussions please contact our Business Development team at jack.chang@allgenesis.com or loris.wu@allgenesis.com. Additional information on Allgenesis’ AG-73305 program and other compounds in the pipeline can be found at www.allgenesis.com
About Allgenesis
Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases, AG-86893 for pterygium, and AG-67650 for wAMD.
About AG-73305
AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is a single fusion protein that simultaneously binds to VEGF and integrins with high potency and specificity. During the discovery stage, AG-73305 demonstrated promising efficacy in preventing breakdown of the blood-retina-barrier in a rabbit POC model and in a laser-induced CNV monkey model. AG-73305 has a desirable ocular pharmacokinetic profile and was well-tolerated in monkeys after intravitreal injection.